🇺🇸 urate oxidase in United States
23 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 23
Most-reported reactions
- Blindness — 3 reports (13.04%)
- Gastrointestinal Disorder — 3 reports (13.04%)
- Multi-Organ Failure — 3 reports (13.04%)
- Pyrexia — 3 reports (13.04%)
- Cerebral Haemorrhage — 2 reports (8.7%)
- Electroencephalogram Abnormal — 2 reports (8.7%)
- Necrosis — 2 reports (8.7%)
- Optic Nerve Injury — 2 reports (8.7%)
- Petit Mal Epilepsy — 2 reports (8.7%)
- Blood Alkaline Phosphatase Increased — 1 report (4.35%)
urate oxidase in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is urate oxidase approved in United States?
urate oxidase does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for urate oxidase in United States?
Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.